Related Experiment Video
Updated: Aug 23, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
[cDNA microarray analysis of gene expression in acquired methotrexate-resistant of human choriocarcinoma]
Ya-xia Chen1, Xing Xie, Qi Cheng
1Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Objective:
To identify the molecular components involved in acquired methotrexate-resistance of human choriocarcinoma.
Methods:
Methotrexate-resistant cell line (JAR/MTX) was derived from JAR cell line by exposed to intervally and progressively increasing higher concentration of MTX. cDNA microarray analyses of JAR/MTX and its parental cell line JAR were performed.
Results:
JAR/MTX was established after one year with stable resistance. Its resistant index to MTX was 7.3. Nine genes were differential expressed between JAR/MTX and JAR cells. INSR, SLC1A3, SAT, HBB, and FLJ12443 were underexpressed and HS1, TXNRD1, TAGLN2, and EEF2 were overexpressed in JAR/MTX cells.
Conclusion:
The cDNA microarray system showed that several alterations of gene expression were present in acquired methotrexate-resistance of human choriocarcinoma.
Insights
This study identified key gene expression changes in acquired methotrexate resistance in human choriocarcinoma. Understanding these molecular alterations is crucial for developing new treatment strategies.
Area of Science:
- Molecular Biology
- Genomics
- Cancer Research
Context:
- Methotrexate is a key chemotherapy drug for treating various cancers, including choriocarcinoma.
- Acquired resistance to methotrexate poses a significant clinical challenge, limiting treatment efficacy.
- Understanding the molecular mechanisms underlying acquired resistance is essential for overcoming treatment failure.
Purpose:
- To identify the specific molecular components and gene expression alterations associated with acquired methotrexate resistance in human choriocarcinoma.
- To compare gene expression profiles between a methotrexate-resistant choriocarcinoma cell line (JAR/MTX) and its parental cell line (JAR).
Summary:
- A methotrexate-resistant choriocarcinoma cell line (JAR/MTX) was successfully established with a resistance index of 7.3.
- cDNA microarray analysis revealed differential expression of nine genes between JAR/MTX and JAR cells.
- Specific genes identified include underexpressed INSR, SLC1A3, SAT, HBB, and FLJ12443, and overexpressed HS1, TXNRD1, TAGLN2, and EEF2.
Impact:
- The findings highlight significant alterations in gene expression patterns contributing to acquired methotrexate resistance in choriocarcinoma.
- This research provides a foundation for further investigation into the roles of identified genes in drug resistance.
- The identified molecular markers may serve as potential therapeutic targets or biomarkers for predicting treatment response in choriocarcinoma.
